Loading...
KMDA logo

Kamada Ltd.NasdaqGS:KMDA Stock Report

Market Cap US$426.5m
Share Price
n/a
1Y-5.1%
7D-0.4%
1D-2.4%
Portfolio Value
​
View

Kamada Ltd.

NasdaqGS:KMDA Stock Report

Market Cap: US$426.5m

Kamada (KMDA) Stock Overview

Manufactures and sells plasma-derived protein therapeutics. More details

KMDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends3/6

Rewards

Trading at 61.2% below our estimate of its fair value

Earnings are forecast to grow 17.43% per year

Earnings have grown 39.6% per year over the past 5 years

Risk Analysis

No risks detected for KMDA from our risk checks.

KMDA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,009 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
501,009 investors already sharing narratives
View all narratives

Kamada Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Kamada
Historical stock prices
Current Share Price₪7.31
52 Week High₪9.35
52 Week Low₪6.50
Beta0.15
1 Month Change1.95%
3 Month Change-13.70%
1 Year Change-5.06%
3 Year Change44.75%
5 Year Change27.35%
Change since IPO-20.97%

Recent News & Updates

Seeking Alpha • Jun 02

Kamada: Undervalued, Yet Execution Risks Keep It A Hold

Summary Kamada Ltd. maintains solid demand and profitability, but near-term margin pressures and execution risks justify a hold rating. FDA approval of the in-house RFFIT lab removes a key operational bottleneck, supporting vertical integration and future growth in the rabies franchise. 1Q26 results showed stable revenues ($45.2M, +3% YoY) and a robust 26% EBITDA margin, offset by gross margin compression and shipment timing effects. KMDA trades at a discount to the sector on FWD EV/EBITDA (7.4x vs. 11.6x), but the market discounts margin sustainability and execution risks despite strong forward growth prospects. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 02

Kamada: Undervalued, Yet Execution Risks Keep It A Hold

Summary Kamada Ltd. maintains solid demand and profitability, but near-term margin pressures and execution risks justify a hold rating. FDA approval of the in-house RFFIT lab removes a key operational bottleneck, supporting vertical integration and future growth in the rabies franchise. 1Q26 results showed stable revenues ($45.2M, +3% YoY) and a robust 26% EBITDA margin, offset by gross margin compression and shipment timing effects. KMDA trades at a discount to the sector on FWD EV/EBITDA (7.4x vs. 11.6x), but the market discounts margin sustainability and execution risks despite strong forward growth prospects. Read the full article on Seeking Alpha
Seeking Alpha • Oct 19

Kamada secures $22M extension of Canadian supply tender

Kamada (NASDAQ:KMDA) was awarded an extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG® and WINRHO® SDF, for an additional three years for an approximate total value of $22M. The award secures the ongoing sales of those products in the Canadian market. The four commercial products, approved by Health Canada and the U.S. Food and Drug Administration were acquired by Kamada in November 2021. CBS manages the Canadian supply of blood products for all Canadian provinces and territories, excluding Quebec. The supply extension secures ongoing sales of approximately $7.5M per year for 2023-2025, with an option to extend for up to additional two years. Commercial manufacturing of CYTOGAM at Kamada’s Israeli manufacturing plant is expected to be initiated during 2023.
Seeking Alpha • Aug 16

Kamada Q2 2022 Earnings Preview

Kamada (NASDAQ:KMDA) is scheduled to announce Q2 earnings results on Wednesday, August 17th, before market open. The consensus EPS Estimate is -$0.02 (-200.0% Y/Y) and the consensus Revenue Estimate is $23.69M (-2.1% Y/Y). Over the last 1 year, KMDA has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Shareholder Returns

KMDAUS BiotechsUS Market
7D-0.4%2.3%0.8%
1Y-5.1%42.3%20.2%

Return vs Industry: KMDA underperformed the US Biotechs industry which returned 42.3% over the past year.

Return vs Market: KMDA underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is KMDA's price volatile compared to industry and market?
KMDA volatility
KMDA Average Weekly Movement4.2%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: KMDA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: KMDA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990462Amir Londonwww.kamada.com

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.

Kamada Ltd. Fundamentals Summary

How do Kamada's earnings and revenue compare to its market cap?
KMDA fundamental statistics
Market capUS$426.49m
Earnings (TTM)US$20.37m
Revenue (TTM)US$181.68m
20.9x
P/E Ratio
2.3x
P/S Ratio

Is KMDA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KMDA income statement (TTM)
RevenueUS$181.68m
Cost of RevenueUS$106.91m
Gross ProfitUS$74.77m
Other ExpensesUS$54.41m
EarningsUS$20.37m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.35
Gross Margin41.16%
Net Profit Margin11.21%
Debt/Equity Ratio0%

How did KMDA perform over the long term?

See historical performance and comparison

Dividends

3.4%
Current Dividend Yield
71%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 23:36
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kamada Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Andrew FeinH.C. Wainwright & Co.
Anthony PetroneJefferies LLC